- Trials with a EudraCT protocol (100)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
100 result(s) found for: Deoxyribonucleic Acid.
Displaying page 1 of 5.
EudraCT Number: 2017-005025-20 | Sponsor Protocol Number: CR0012 | Start Date*: 2018-03-21 |
Sponsor Name:UCB Biosciences, Inc. | ||
Full Title: An open-label, multicenter study to assess the safety of certolizumab pegol in children and adolescents with active Crohn's Disease who completed C87035 or who were terminated from C87035 when the ... | ||
Medical condition: Crohn´s Disease | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-004266-26 | Sponsor Protocol Number: RIVAROXACS2002 | Start Date*: 2015-04-13 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban versus Acetylsalicylic Acid in Addition to Either Clopidogrel or ... | |||||||||||||
Medical condition: Acute Coronary Syndrome (ACS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) SE (Completed) CZ (Completed) NL (Completed) HU (Completed) ES (Completed) IT (Completed) BG (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004795-35 | Sponsor Protocol Number: CMX001-301 | Start Date*: 2014-06-02 | |||||||||||
Sponsor Name:Chimerix, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection ... | |||||||||||||
Medical condition: Cytomegalovirus (CMV) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003028-19 | Sponsor Protocol Number: PS_KSS_001_2019 | Start Date*: 2019-10-30 | |||||||||||||||||||||||||||||||
Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA | |||||||||||||||||||||||||||||||||
Full Title: Clinical-instrumental definition of the phenotypic spectrum, response to treatment and natural history in Pearson and Kearns-Sayre syndrome | |||||||||||||||||||||||||||||||||
Medical condition: Pearson and Kearns-Sayre syndrome. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005262-35 | Sponsor Protocol Number: 16401 | Start Date*: 2013-07-08 | ||||||||||||||||
Sponsor Name:Bayer HealthCare AG | ||||||||||||||||||
Full Title: BENEFIT 11 a long-term, follow-up study (16401) of the BENEFIT (304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to further evaluate the progress of patients with fi... | ||||||||||||||||||
Medical condition: Clinically isolated syndrome (CIS) and multiple sclerosis (MS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) SE (Completed) PT (Completed) HU (Completed) CZ (Completed) NO (Completed) AT (Completed) FI (Completed) DK (Completed) GB (Completed) ES (Completed) IT (Completed) SI (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-002767-95 | Sponsor Protocol Number: 12/0161 | Start Date*: 2013-06-17 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Long term antibody response to CMV gB vaccine in patients requiring liver or renal transplant. A Phase II open, single-site study, in participants who received CMV gB vaccine or placebo in previous... | |||||||||||||
Medical condition: Cytomegalovirus. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006208-52 | Sponsor Protocol Number: IFN005 | Start Date*: 2009-03-09 | |||||||||||
Sponsor Name:Helix BioPharma Cooperation | |||||||||||||
Full Title: Mono-centre, open-label study to investigate the multi-dose pharmacokinetics, efficacy and safety of Interferon alpha-2b Cream in women with a history of cytological diagnosed Pap IIID, with a con... | |||||||||||||
Medical condition: cervical dysplasia (CIN I or CIN II; Pap IIID in the history, confirmed HPV+ status) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005525-63 | Sponsor Protocol Number: C87044 | Start Date*: 2006-02-16 | |||||||||||
Sponsor Name:UCB Pharma S.A. | |||||||||||||
Full Title: Follow-up of study C87040 : Multicenter, single blind study to describe the efficacy and safety of re-treatment with CDP870 (certolizumab pegol) subcutaneous at 2 different dose regimens (400 mg i... | |||||||||||||
Medical condition: Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003984-37 | Sponsor Protocol Number: CMX001-211 | Start Date*: 2018-07-30 | |||||||||||
Sponsor Name:Chimerix, Inc | |||||||||||||
Full Title: A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients with Adenovirus Viremia | |||||||||||||
Medical condition: Treatment of adenovirus infections in adult allogeneic hematopoietic cell transplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000126-30 | Sponsor Protocol Number: ASM8-A-208 | Start Date*: 2011-06-07 | ||||||||||||||||
Sponsor Name:Pharmaxis Ltd | ||||||||||||||||||
Full Title: A phase II, multi-centre, single blind study to evaluate the safety, tolerability and explore the efficacy of 8.0 mg ASM8 inhaled daily for 14 days in adult subjects with moderate to severe asthma | ||||||||||||||||||
Medical condition: moderate to severe asthma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003818-24 | Sponsor Protocol Number: DC2015RED01 | Start Date*: 2015-12-11 |
Sponsor Name:VU University Medical Center | ||
Full Title: A phase 4, monocenter, randomized, double-blind, comparator-controlled, parallel-group, mechanistic intervention trial to assess the effect of 12-week treatment with the sodium-glucose linked trans... | ||
Medical condition: Type 2 Diabetes Mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-005604-35 | Sponsor Protocol Number: APEC1621B | Start Date*: 2022-01-18 | |||||||||||
Sponsor Name:National Cancer Institute (NCI) | |||||||||||||
Full Title: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations | |||||||||||||
Medical condition: Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002694-11 | Sponsor Protocol Number: D5160C00007 | Start Date*: 2014-12-17 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: A phase III, double-blind, randomised study to assess the efficacy and safety of AZD9291 versus a standard of care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as first-line treatment... | ||||||||||||||||||
Medical condition: Locally advanced or metastatic non-small cell lung cancer, not amenable to curative surgery or radiotherapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) GB (GB - no longer in EU/EEA) IT (Completed) DE (Completed) ES (Completed) BE (Completed) SE (Completed) CZ (Completed) FR (Completed) PL (Completed) BG (Completed) PT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001966-39 | Sponsor Protocol Number: CBYL719C2303 | Start Date*: 2021-09-27 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advan... | |||||||||||||
Medical condition: Hormone receptor positive, HER2-negative advanced breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) HU (Ongoing) SK (Ongoing) CZ (Ongoing) IT (Ongoing) IE (Ongoing) ES (Ongoing) BE (Ongoing) FI (Ongoing) DK (Ongoing) PT (Ongoing) BG (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001547-12 | Sponsor Protocol Number: DC2017RACELINES01 | Start Date*: 2017-12-21 |
Sponsor Name:VU University Medical Center | ||
Full Title: A phase 4, monocenter, randomized, double-blind, comparator-controlled, 3-armed parallel mechanistic intervention trial to assess the effect of 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, ... | ||
Medical condition: Type 2 Diabetes Mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001973-42 | Sponsor Protocol Number: 109MS310 | Start Date*: 2015-12-17 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: An Open-Label Study to Assess the Effects of BG00012 on Lymphocyte Subsets in Subjects With Relapsing-Remitting Multiple Sclerosis | |||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) LT (Completed) PL (Completed) BG (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000988-14 | Sponsor Protocol Number: CCD05 | Start Date*: 2016-10-12 |
Sponsor Name:PROMETHERA Biosciences S.A./N.V. | ||
Full Title: Title: Open, Prospective, Historic-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Infusion of Liver Cell Suspension (HHLivC) in Children with Urea Cycle Disorders | ||
Medical condition: Neonatal-onset type of the following urea cycle disorders (UCD): ornithine transcarbamylase deficiency (OTCD), carbamoylphosphate synthetase I deficiency (CPS1D), or argininosuccinate synthetas... | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2013-005586-39 | Sponsor Protocol Number: 101MS409 | Start Date*: 2015-01-29 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching from BRACET/Gilenya® to Natalizumab in Subjects with Relapsing Forms of Multiple Sclerosis (MS) | |||||||||||||
Medical condition: Multiple Sclerosis (MS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001808-11 | Sponsor Protocol Number: ID-064A202 | Start Date*: 2019-01-14 | |||||||||||
Sponsor Name:Idorsia Pharmaceuticals Ltd | |||||||||||||
Full Title: A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in subjects with moderate to severe syste... | |||||||||||||
Medical condition: Moderate to severe systemic lupus erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) HU (Completed) BG (Completed) PL (Completed) GR (Completed) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002488-91 | Sponsor Protocol Number: MO39874 | Start Date*: 2019-11-04 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: AN OPEN-LABEL, PHASE IIIB, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) PLUS NAB-PACLITAXEL IN THE TREATMENT OF UNRESECTABLE LOCALLY ADVANCED OR METASTATIC PD-L1-POSITIVE TRIPLE-NEGATI... | |||||||||||||
Medical condition: Unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Ongoing) SI (Ongoing) FR (Ongoing) HU (Ongoing) SK (Ongoing) IT (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.